Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency as Open Label Extension

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03512314
Recruitment Status : Recruiting
First Posted : April 30, 2018
Last Update Posted : October 22, 2020
Sponsor:
Information provided by (Responsible Party):
AB2 Bio Ltd.

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 30, 2021
Estimated Study Completion Date : February 28, 2022